These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36591781)

  • 1. HOMOCYSTEINE AND CARDIOVASCULAR DISEASE - A CURRENT REVIEW.
    Gospodarczyk A; Marczewski K; Gospodarczyk N; Widuch M; Tkocz M; Zalejska-Fiolka J
    Wiad Lek; 2022; 75(11 pt 2):2862-2866. PubMed ID: 36591781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems.
    Djuric D; Jakovljevic V; Zivkovic V; Srejovic I
    Can J Physiol Pharmacol; 2018 Oct; 96(10):991-1003. PubMed ID: 30130426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperhomocysteinemia: an additional cardiovascular risk factor.
    Fanapour PC; Yug B; Kochar MS
    WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hyperhomocysteinemia on cardiovascular risk factors and initiation of atherosclerosis in Wistar rats.
    Sharma M; Rai SK; Tiwari M; Chandra R
    Eur J Pharmacol; 2007 Nov; 574(1):49-60. PubMed ID: 17706635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M;
    Clin Chem Lab Med; 2003 Nov; 41(11):1392-403. PubMed ID: 14656016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia.
    Steed MM; Tyagi SC
    Antioxid Redox Signal; 2011 Oct; 15(7):1927-43. PubMed ID: 21126196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases.
    Stanger O; Herrmann W; Pietrzik K; Fowler B; Geisel J; Dierkes J; Weger M
    Z Kardiol; 2004 Jun; 93(6):439-53. PubMed ID: 15252738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperhomocysteinemia and Cardiovascular Disease: Is the Adenosinergic System the Missing Link?
    Paganelli F; Mottola G; Fromonot J; Marlinge M; Deharo P; Guieu R; Ruf J
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhomocysteinemia and cardiovascular disease in animal model.
    Azad MAK; Huang P; Liu G; Ren W; Teklebrh T; Yan W; Zhou X; Yin Y
    Amino Acids; 2018 Jan; 50(1):3-9. PubMed ID: 29018979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperhomocysteinemia: an independent risk factor or a simple marker of vascular disease?. 1. Basic data].
    Guilland JC; Favier A; Potier de Courcy G; Galan P; Hercberg S
    Pathol Biol (Paris); 2003 Mar; 51(2):101-10. PubMed ID: 12801808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hyperhomocysteinemia--a risk factor for development of occlusive vascular diseases].
    Milosević-Tosić M; Borota J
    Med Pregl; 2002; 55(9-10):385-91. PubMed ID: 12584890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperhomocysteinemia and cardiovascular diseases.
    Guieu R; Ruf J; Mottola G
    Ann Biol Clin (Paris); 2022 Feb; 80(1):7-14. PubMed ID: 35129442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of increased vascular oxidant stress in hyperhomocys-teinemia and its impact on endothelial function.
    Weiss N
    Curr Drug Metab; 2005 Feb; 6(1):27-36. PubMed ID: 15720205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular oxidant stress and inflammation in hyperhomocysteinemia.
    Papatheodorou L; Weiss N
    Antioxid Redox Signal; 2007 Nov; 9(11):1941-58. PubMed ID: 17822365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperhomocysteinemia and cardiovascular risk: effect of vitamin supplementation in risk reduction.
    Ciaccio M; Bellia C
    Curr Clin Pharmacol; 2010 Feb; 5(1):30-6. PubMed ID: 20236081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Homocysteine and hyperhomocysteinemia].
    Laskowska-Klita T
    Pol Merkur Lekarski; 2001 Mar; 10(57):135-7. PubMed ID: 11398509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperhomocysteinemia and the disturbance of haemostasis--facts and mythes].
    Malinowska J; Nowak P; Olas B
    Pol Merkur Lekarski; 2009 Nov; 27(161):413-8. PubMed ID: 19999808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MTHFR gene polymorphism, homocysteine and cardiovascular disease.
    Cortese C; Motti C
    Public Health Nutr; 2001 Apr; 4(2B):493-7. PubMed ID: 11683544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperhomocysteinemia in patients with cardiovascular disease].
    Baszczuk A; Kopczyński Z
    Postepy Hig Med Dosw (Online); 2014 Jan; 68():579-89. PubMed ID: 24864108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current status of homocysteine as a risk factor for cardiovascular disease: a mini review.
    Chrysant SG; Chrysant GS
    Expert Rev Cardiovasc Ther; 2018 Aug; 16(8):559-565. PubMed ID: 29979619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.